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Abstract The Gag and Gag-Pol precursors of avian sarcoma 
leukemia virus (ASLV) are translated from viral genomic-size 
mRNA at a molar ratio of about 20:1. Translation of Gag is 
terminated at the stop codon UAG located at the carboxyl-termi- 
nus of the viral protease (PR), whereas a ribosomal frameshift 
occurring at the carboxyl-terminus of Gag allows translation of 
the Gag-Pol precursor. To determine how PR is released from 
the Gag-Pol precursor, a single base (A or T) was inserted at the 
Gag-Pol junction in order to adjust the translation into a single 
reading frame. These mutations allow processing of the viral 
precursor when expressed in bacterial cells, but cause cessation 
of viral production after transfection of avian cells. The viral PR 
released from the large precursor is one amino acid longer than 
PR cleaved from the Gag polyprotein and is terminated by an Ile 
instead of a Leu residue. 
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1. Introduction 
Retroviral Gag and Gag-Pol precursors are translated from 
the genomic-size mRNA [1]. In avian sarcoma leukemia viruses 
(ASLV) the Gag-Pol precursor is translated via a ribosomal 
frameshift (FS) which takes place at the carboxyl-terminus of
Gag [2,3]. The Gag and Gag-Pol precursors are cleaved into 
mature structural and enzymatic proteins by a viral-encoded 
protease (PR) during virion assembly or even after virus re- 
lease. The 15 kDa (124 amino acid residues) PR of ASLV 
resides at the carboxyl-terminus of pr76 Gag and at the Gag-Pol 
junction of prlS0 Gag'p°l precursors, while in mammalian retro- 
viruses it is a part of the Gag-Pol precursor only. The produc- 
tion of pr766~'g and pr 180 G"g-P°j polyproteins at a molar ratio of 
20: 1 is regulated by ribosomal frameshifting which takes place 
at the A AAT TTA TA region located at the 3' end of the gag 
region, and which codes for Asn-Leu-Ile at the Gag-Pol junc- 
tion [1 3]. 
The HIV-1 Gag and Pol genes positioned in the same trans- 
lational reading frame underwent autocatalysis when expressed 
in COS cells [4]. On the other hand, ASLV Gag-Pol fusion 
polyprotein expressed in avian and mammalian cells remained 
unprocessed. The processing of this viral prl80 GagP°l can be 
complemented by co-expression of the Gag protein from a 
separate vector [5]. To determine whether ASLV protease m- 
bedded in the Gag-Pol precursor is enzymatically active, we 
expressed the fusion proteins in bacterial cells and followed 
their autoprocessing. 
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Here we demonstrate that the ribosomal ffameshift which is 
essential for virus production, generates a novel cleavage site 
for viral PR. Gag and Pol polyproteins which were adjusted to 
a single reading frame undergo autocleavage in bacterial cells 
to release PR and mature viral proteins. Cleavage by viral PR 
of synthetic peptides homologous to the Gag-Pol junction sug- 
gests that PR released from the pr180 °agP°~ precursor contains 
125 amino acid residues instead of the 124 present in PR 
cleaved from pr76 gag, and that Ile replaces Leu at the carboxyl- 
terminus. 
2. Materials and methods 
2.1. Bacterial cells 
The E. coli strain MC1061 was used as the host for all expression 
vectors. The cells contained the plasmid pRK248cIts, which directs the 
expression of a temperature-sensitive bacteriophage lambda repressor 
protein [6]. 
The E. coli strain DR 100 was used as the host for pBR322 containing 
the permutated Schmidt Ruppin A provirus (pSRA) [7] obtained from 
Dr. S. Hughes (National Cancer Institute, Frederick, MD). This vector 
was used for preparing the FS- mutated proviral DNAs for the transfec- 
tion experiments. 
2.2. Construction of bacterial clones 
A viral PstI-BamHI fragment (2455 3708 [8]) derived from pATV8, 
a clone of the avian sarcoma Prague C strain [9], was inserted into the 
pUC18 plasmid. This construct was used to mutate the gag-pol 
frameshift region by site-directed mutagenesis, as described before 
[10,11]. The oligonucleotides u ed for mutagenesis were derived from 
the wt sequence: 
wt-  5 'CGC TTA ACA AAT TTA TAG GGA GGG CCA CTG TTC TCA 
FSI-  5 'CGC TTC ACAAAT TTAaTAGGt  cGa GCC ACT GTT CTC 
FS2- 5 'CGC TTGACAAATtTT  ATA GGT cGa GCGACT GTT CTC 
FS3- 5 'CGC TTG ACAAATtTT  ccc GGGAGA GCC ACT GTT CTC 
(small letters indicate the mutated bases). 
The wild type (wt) and the mutated Pstl-BamHI fragments were 
excised from the pUC18 constructs and ligated to a BamHI PstI frag- 
ment derived from pRT [12] and to the PstI-PstI fragment taken from 
pPR, pNC-PR or pNC-PR ASp37"e [13] to generate plasmids with pFS1 
and pFS2. The Pstl-Pstl fragment supplies the lambda phage promoter 
operator region (PLOL), a ribosomal binding site and translation i itia- 
tor codon in frame with the viral CA protein. The PstI.-PstI fragment 
• , 37  . . . .  
derived from pNC-PR Aw ,e provides an lnactwe PR [10]. Expression 
of the viral proteins in bacterial cells was induced by shifting cultures 
from 30°C to 42°C for 3 6 h, and virus-related proteins were detected 
by immunoblotting asdescribed elsewhere [10]. 
Plasmids containing the viral genomic DNA with the frameshift 
mutations (pSRAFS1-3) were generated by ligation ofSacl EcoRI and 
SacLKpnI fragments ofpSRA with the EcoRI Kpnl fragments derived 
from pFS1, 2, or 3. 
2.3. Tran4fection experiments 
DNAs prepared from pSRAFS1, 2 and 3 were linearized by cutting 
with SalI and ligated to form linear genomic viral molecules. Sub- 
confluent QT-6 cells [14] were transfected with 10 fig of wt or mutated 
proviral DNA per 100 mm culture plate (Nunc), using a standard 
calcium phosphate transfection protocol [15]. 
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2.4. Reverse transcriptase assay 
Media harvested from transfected QT-6 cultures were cleared of cell 
debris by centrifugation. 5/ll of the supernatant was used in 10/11 
reaction medium to detect reverse transcriptase activity using 
poly-A:oligo-dT as primer template and [32p]TTP (specific activity 
3000 mCi/mmol: New England), as described before [16]. 
2.5. Synthesis and cleavage of peptide substrates 
The synthetic peptides: 
FSl-  NH 2 Arg  Leu Thr  Ash  Leu I le G lyArg  A la  Thr COOH 
FS2-  NH 2 Arg  Leu Thr Asn  Phe I le G lyArg  A la  Thr  COOH 
FS3- NH 2 Arg  Leu Thr  Asn  Phe Pro G ly  Arg  A la  Thr  COOH 
have the same amino acid sequence asthe mutated Gag-Pol junctions. 
Decapeptide NH, Thr Phe Glu Ala Phe-Pro Leu Arg Glu Ala COOH 
is homologous tothe ASLV RT-IN junction and NH2 Thr Phe Glu Ala 
Ala-Pro Leu Arg Glu Ala COOH contains a mutated amino acid which 
prevents cleavage by the viral PR. All synthetic peptides were synthe- 
sized by the solid-phase method [I7]. 
Proteolytic reactions were carried out in 20/A of 0.1 M sodium citrate 
buffer (pH 5.5) containing 16 pmol of PR, 7.7 nmol of a decapeptide 
substrate and 0.4 M sodium chloride, at 37°C for 1 h. Reactions were 
stopped by incubation at 100°C, and the reaction products were ana- 
lyzed by HPLC as described before [18]. 
2.6. Amino acid anaO~sis 
Amino acid content was determined by the PICOTAG method on 
a Water Chromatography Division with minor modifications. 
3. Results 
3.1. Ribosomal frameshifi is essential Jor viral production 
Plasmids containing the SRA and the mutated SRA viral 
DNA (pSRAwt, pSRAFSI, pSRAFS2 and pSRAFS3) were 
used to transfect QT-6 cell cultures in order to verify that the 
ribosomal frameshift is indeed essential for ASLV production 
in permissive cells. Media collected from the transfected cells 
were clarified by centrifugation and assayed for reverse tran- 
scriptase (RT) activity. As can be seen in Fig. 1, particles with 
RT activity were detected in media harvested from cultures 
transfected with pSRAwt, but not in media collected from those 
transfected with viral DNA containing the gag pol region in 
frame (pSRAFS1, -2 and -3). In addition, media harvested from 
cells transfected with pSRAwt, but not with pSRAFSI and 
pSRAFS2, contained viral particles which were detected with 
anti-CA sera and which were infectious in fresh QT-6 cells (data 
not shown). Similar results, demonstrating that the production 
of ASLV and HIV-1 particles are dependent on ribosomal 
frameshifting and that murine leukemia virus production is 
dependent on the amber codon located between the gag pol 
regions, have been published previously [4,5,19-21]. It is possi- 
ble that PR expressed as part of prl80 ~ag-P°~ is not active in 
processing viral precursors. 
3.2. Processing of ASL V Gag-Pol fusion proteins expressed in
E. coli 
Gag-Pol polyproteins containing the NC-PR-RT-IN frag- 
ment with Leu-Ile-Gly (FSI) or Phe-Ile-Gly (FS2) at the Gag- 
Poljunctions were expressed inbacterial cells. Immunoblots of
bacterial extracts, when developed with anti-PR (Fig. 2A), 
showed that both polyproteins underwent autocleavage to re- 
lease PR. The PR released from the Gag-Pol polyproteins had 
a migration coefficient similar to PR expressed alone or re- 
leased from NC-PR dipeptides [10]. PR was not released when 
Asp37[le mutated inactive PR " " was expressed as part of pFS1 and 
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Fig. 1. Reverse transcriptase assay of transfected QT-6 cell culture 
supernatant. QT-6 cultures were transfected with pSRAwt and 
pSRAFS clones. 24, 48 and 72 h post-transfection, thereverse tran- 
scriptase l vel was determined in the culture supernatant. 32p-Labeled 
DNA products were spotted onto DEAE paper as previously described 
[16], and the paper was exposed to X-ray film. Media from untrans- 
fected cells and from pSRA-transfected cells were used as negative and 
positive controls. 
pFS2, indicating that processing of the viral precursors was 
carried out by viral, and not cellular, proteins. Several proteins, 
larger than viral PR and reactive to anti-PR, were present on 
the blot (Fig. 2A). These proteins resulted from partial process- 
ing of the polyproteins. 
Fig. 2B and C demonstrate hat the NC-PR-RT-IN fusion 
proteins containing FS1 or FS2 sequences underwent process- 
ing in bacterial cells. The viral proteins are cleaved into Pol 
precursor pr95 and into the mature proteins p63 (RT) and p32 
(IN). Thus the pr95 reacts with anti-RT and anti-IN (Fig. 2B 
and C) while the p32 and p63 proteins are detected in B and 
C, respectively. The pPRvslRT-IN is cleaved into IN (p32) and 
RT (p63) but not into pr95 (B and C). 
3.3. Cleavage of synthetic peptides representing the Gag-Pol 
junction 
The synthetic peptides FS 1 and FS2 were used as substrates 
for PR hydrolysis in order to determine the cleavage sites at the 
ASLV Gag-Pol junction. Fig. 3 clearly indicates that decapep- 
tides FS1, but not FS2, are cleaved by PR, implying that a 
decapeptide containing Asn Leu Ile Gly, but not Asn Phe Ile 
Gly, is an efficient substrate for PR (Fig. 3). Decapeptides 
containing Phe-Pro or Ala-Pro at the cleavage site were used 
as positive and negative controls, respectively, for the PR activ- 
ity as shown before [18]. 
Amino acid analysis of the cleavage products isolated after 
PR hydrolysis howed that product #1 contained Arg, Leu, 
Thr, Asn, Ile; and product #2 contained Gly, Arg, Ala, Thr. 
These results indicate that the FS1 decapeptide was cleaved 
between the Ile and Gly residues. If in vitro cleavage of the 
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Fig. 2. Expression and processing of ASLV polyproteins in E. coli. Lysates of E. coli strains that express the indicated viral polyproteins were 
fractionated on sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose paper. ASLV polypeptides were detected by antibody 
to PR (A), anti-IN (B) and with anti-RT (C). Reaction products were detected with '35I-labeled protein A. Molecular weights (× 1000) are indicated 
on the left. The arrows indicate the position PR, IN and RT released from the viral polyproteins. 
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Fig. 3. Comparison of cleavage products of FS1 and FS2 peptides by using purified ASLV PRs. Reaction mixtures containing FS2 (A and C), or 
FS 1 peptides (B and D) were incubated at 37°C with (lower panels) or without (upper panels) purified PR. Samples were taken after 60 min incubation 
time and were analyzed by HPLC. S, P1 and P2 indicate substrate and cleavage products, respectively. 
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synthetic peptides indeed mimics the in vivo processing of the 
viral Gag-Pol precursor, then PR released from pr 180 gag-p°t con- 
tains 125 amino acid residues instead of the 124 in PR released 
from the pr76 gag precursor, lie is the amino acid at the carboxyl- 
terminus of PR released from prl80 °ag-P°l, being the 125th res- 
idue, as opposed to #124, Leu, positioned at the carboxyl- 
terminus of Gag. 
4. Discussion 
Mature avian sarcoma leukemia virions contain free PR mol- 
ecules which are probably released from the pr76 g~g and 
prl80 g"g-p°l precursors. Release of PR and other viral proteins 
from Gag-Pol polyproteins expressed in bacterial cells via FS1 
and FS2 mutations suggests that the PR embedded in the Gag- 
Pol precursor is enzymatically active and that amino acid se- 
quences located at the carboxyl region of PR contain a cleavage 
site for the viral PR. Previously, it was shown that the ASLV 
but not HIV-1 Gag-Pol fusion proteins expressed in mammal- 
ian cells was unable to carry out auto-processing [4,5]. It is 
therefore possible that correct conformation of the PR domain 
in the fusion protein or/and high local concentrations of the 
large precursors are required to activate the PR embedded in 
the Gag-Pol precursors. 
Decapeptides containing the junction region of mature Gag- 
Pol proteins are specific and efficient substrates for viral PR 
[18,22,23]. Because it is extremely difficult to analyze the car- 
boxyl-terminus of PR released from prl80 C"gp°~, we assayed 
whether FS1 and FS2 decapeptides are cleaved by purified 
ASLV PR. Based on the amino acid composition of the cleav- 
age products, we suggest hat PR released from the Gag-Pol 
precursor contains 125 amino acid residues, instead of the 124 
residues in PR released from the Gag precursor. In contrast o 
the results obtained in bacterial cells, where PR was released 
from polyproteins expressed via FS1 and FS2 mutations, syn- 
thetic decapeptides homologous to FS1 were cleaved by PR in 
vitro. However, it is possible that in bacterial cells, PR is re- 
leased from the FS2 frameshift polyprotein by cleavage at a 
site which is not accessible for PR hydrolysis in the FS2 deca- 
peptide. 
Jacks and co-workers [2,3] demonstrated that a ribosomal 
frameshift occurring during translation of ASLV genomic 
mRNA leads to expression of Leu-Ile residues (FSI) at the 
Gag-Poljunction. However, an additional A to U 'slippery site' 
resulting in a Phe-Ile junction (FS2) may exist, as suggested by 
Majors [24]. At present, we cannot negate the possibility that 
the Gag-Pol precursor is formed via FS1 and FS2. However, 
translation via FS1 is a more favorable possibility since transla- 
tion of a sequence coding for Leu-Ile was demonstrated in vitro 
[2,3], and this junction creates a cleavage site very close to the 
terminus of PR released from the Gag precursor. 
It is of interest that retroviral proteases cleave the precursors 
close to the Gag-Pol junction. For example, in HIV-1, as in 
ASLV, PR cleaves 6-7 amino acids downstream of the frame- 
shift sites, namely at the amino-termini of RT and p6 p°~ of 
ASLV and HIV-1, respectively [25 27]. Additional cleavage 
sites are present close to the frameshift site, namely in ASLV 
lle/Gly at the Gag-Pol junction (as shown in this report), and 
in HIV-1 Asn/Phe at the NC/P1 junction [28]. It therefore seems 
that over evolutionary times a mechanism has been preserved 
which ensures complete separation of the translation products 
of Gag and Pol. 
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